Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Clonal Hematopoeisis of undetermined potential

Tarek H Mouhieddine • 13 Sep 2019
IMW 2019
Multiple Myeloma

Tarek H Mouhieddine, MD, Dana-Farber Cancer Institute, Boston, MA, discusses how multiple myeloma patients with clonal hematopoeisis of undetermined potential (CHIP) are at an increased risk of cardiovascular disease and additional hematological malignancies. Dr Mouhieddine goes on to explain how immunomodulatory maintenance negates the negative effects of CHIP. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Tarek H Mouhieddine

5:20
The evolution of clonal hematopoiesis and associated outcomes in multiple myeloma
Tarek H Mouhieddine • 9 Dec 2023
4:44
Investigating immune dynamics in multiple myeloma treated with talquetamab monotherapy
Tarek H Mouhieddine • 9 Dec 2023
2:19
Clonal hematopoiesis in patients with multiple myeloma
Tarek H Mouhieddine • 11 Dec 2021
2:22
Outcomes and management of patients with R/R myeloma who progress on bispecific antibodies
Tarek H Mouhieddine • 11 Dec 2021

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals